HIV Clinical Trials Market Size To Reach $2.11 Billion By 2030

HIV Clinical Trials Market Growth & Trends 

The global HIV clinical trials market size is estimated to reach USD 2.11 billion by 2030, registering to grow at a CAGR of 5.8% from 2025 to 2030 according to a new report by Grand View Research, Inc. The main drivers of this market are increasing HIV vaccine trials, increased R&D activities for HIV clinical trials, and rising HIV infection awareness, which leads to a large number of patients enrolling in clinical trials. During the COVID-19 pandemic, there was a halt in the market growth.

This decrease in HIV and AIDS clinical trials is due to stay-at-home orders by the government to prevent COVID-19 that led to canceled and delayed trials. It also includes disruption in patient recruitment, hurdles in the conduction of clinical trials, and rapid study for the development of vaccines and medical products for the prevention of COVID-19 that lead to detrimental effects in HIV clinical trial studies. However, these impacts were significantly reduced by adopting strategic measures taken by the clinical trial conducting organization, regulatory authorities, and government bodies.

According to the WHO, in 2020, there were around 37.7 million people infected with HIV infection. To reduce this number, increasing funding and partnerships by biotechnology and pharmaceutical firms have been observed. Moreover, increasing initiatives are being taken by the government to find treatment and spread awareness regarding this disease. For instance, in October 2021, Samsung BioLogics collaborated with Enzolytics Inc. This partnership aims to manufacture Anti-HIV and Anti-SARS-CoV-2 Monoclonal Antibody Therapies.

However, a lack of awareness regarding HIV clinical research trials and the availability of treatments for preventing it are factors that are hindering the growth of this market. According to a report by BioMed Central Ltd. in Europe, out of 467 participants, about one-third of them were not aware of the HIV infection. As a result, ignorance and unawareness regarding the disease will prevent admission to an HIV clinical trial.

 Request a free sample copy or view the report summary: HIV Clinical Trials Market Report

HIV Clinical Trials Market Report Highlights

• In 2024, the phase III segment dominated the HIV clinical trials industry, accounting for a revenue share of 30.0%. Phase I studies help to assess the drug's safety & toxicity at different levels of dose & determine drug pharmacokinetics.

• In 2024, the interventional studies segment dominated the HIV clinical trials industry, accounting for a revenue share of 69.8%.

• The pharmaceutical and biopharmaceutical companies segment accounted for the largest market share in 2024.

• North America HIV clinical trials market dominated the global market in 2024 with the largest share of 47.3%. This can be attributed to the increased number of HIV clinical trials being conducted in the region. V

HIV Clinical Trials Market Segmentation

Grand View Research has segmented the global HIV clinical trials market based on phase, study design, sponsor, and region:

HIV Clinical Trials Phase Outlook (Revenue, USD Million, 2018 - 2030) 

• Phase I

• Phase II

• Phase III

• Phase IV

HIV Clinical Trials Study Design Outlook (Revenue, USD Million, 2018 - 2030)          

• Interventional Studies

• Observational Studies

• Expanded Access Studies

HIV Clinical Trials Sponsor Outlook (Revenue, USD Million, 2018 - 2030)        

• Pharmaceutical & Biopharmaceutical Companies

• Non-Profit Organizations

• Others

HIV Clinical Trials Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America

  • U.S.

  • Canada

  • Mexico

• Europe

  • UK

  • Germany

  • France

  • Italy

  • Spain

  • Sweden

  • Denmark

  • Norway

• Asia Pacific

  • Japan

  • China

  • India

  • Thailand

  • South Korea

  • Australia

• Latin America

  • Brazil

  • Argentina

• Middle East & Africa

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait

List of Key Players in the HIV Clinical Trials Market

• PPD Inc.

• IQVIA Inc.

• Parexel International Corporation

• ICON plc

• Syneos Health

• WuXi AppTec

• Janssen Global Services, LLC

• Gilead Sciences, Inc.

• Bionor Holding AS

• Charles River Laboratories

• GSK plc.

• SGS SA